LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 68.15 +2.15 (+3.26%) As of 05/15/2026 08:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 62▼ 7050-Day Range 62▼ 7552-Week Range 40▼ 100Volume45,015 shsAverage Volume15,412 shsMarket Capitalization£25.73 millionP/E Ratio34.08Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target. Read More Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AREC Stock News HeadlinesArecor Therapeutics (LON:AREC) Trading Up 6.1% - Here's What HappenedMay 6, 2026 | americanbankingnews.comArecor Therapeutics CEO on advancing ultra-rapid insulin trial and oral GLP-1 - ICYMIApril 17, 2026 | proactiveinvestors.com.auYou're not getting into the SpaceX IPO. Do this instead.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost. | Behind the Markets (Ad)Arecor targets broader AT278 partnership as phase II trial nearsApril 13, 2026 | uk.finance.yahoo.comArecor targets phase II trial for AT278 in 2026 - ICYMIFebruary 14, 2026 | uk.finance.yahoo.comArecor targets phase II insuling trial for 2026 after successful 2025February 11, 2026 | finance.yahoo.comRainbow Rare Earths, Cloudbreak Discovery, Valereum, Arecor Therapeutics, Wellnex LifeFebruary 9, 2026 | finance.yahoo.comArecor prioritises deal for phase II insulin trial as key 2026 objectiveFebruary 9, 2026 | uk.finance.yahoo.comSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 84.45 at the beginning of 2026. Since then, AREC shares have decreased by 19.3% and is now trading at GBX 68.15. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) issued its earnings results on Monday, April, 13th. The company reported $2.00 earnings per share for the quarter. The firm earned $1.71 million during the quarter. Arecor Therapeutics had a net margin of 38.74% and a trailing twelve-month return on equity of 14.26%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings4/13/2026Today5/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 2 Trailing P/E Ratio34.08 Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.68 million Net Margins38.74% Pretax MarginN/A Return on Equity14.26% Return on Assets-37.31% Debt Debt-to-Equity Ratio1.52 Current Ratio4.35 Quick Ratio6.24 Sales & Book Value Annual Sales£1.71 million Price / Sales15.01 Cash FlowGBX 13.44 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book4.11Miscellaneous Outstanding Shares37,757,000Free FloatN/AMarket Cap£25.73 million OptionableNot Optionable Beta-0.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (LON:AREC) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe NASTY TRUTH about the SpaceX IPOIn nearly every major IPO, roughly 95% of the gains are captured before retail investors can place a trade. It...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
